A 4-Week, Open-Label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With up-Titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity.
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2013
At a glance
- Drugs Darifenacin (Primary)
- Indications Detrusor instability
- Focus Therapeutic Use
- Sponsors Bayer
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2006-002361-39).
- 23 Feb 2009 New trial record